ARTICLE | Emerging Company Profile
Virion: Harnessing viral defects
Why Virion believes its antivirals have lower potential for resistance
November 16, 2018 1:14 AM UTC
Virion Biotherapeutics Ltd. has capitalized on a naturally occurring viral mutation to develop broad-spectrum antivirals with lower potential for resistance than marketed products. Its lead compound, VH244, is in preclinical development to treat respiratory infections including influenza and respiratory syncytial virus.
“Emergence of resistance is a major concern for antiviral therapeutics,” said CEO Vanessa King, citing an increase in strains resistant to marketed treatments for influenza and RSV. ...